Recursion Pharmaceuticals
RXRX
2.45
-0.27
-9.93%
Recursion Pharmaceuticals
US · RXRX
#2649 by market cap
Listed 2021
2.45
-0.27
-9.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
Recent news
-
Rating change
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold RatingMarket Newswire · 2026/9/21
-
Recursion Pharmaceuticals | 8-K: Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as ChairSEC · 2026/11/3
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)TipRanks · 2026/9/16
-
Recursion Pharmaceuticals | 10-Q: Quarterly reportSEC · 2026/11/3
-
Rating change
Morgan Stanley Remains a Hold on Recursion Pharmaceuticals (RXRX)TipRanks · 2026/10/16
-
Rating change
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8Market Newswire · 2026/10/19
-
Rating change
Bank of America Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)TipRanks · 2026/10/16
-
Company notice
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson BlakeSEC · 2026/11/5
-
Rating change
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.9Market Newswire · 2026/10/16
-
News Flash: Analysts Just Made A Meaningful Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ForecastsSimply Wall St · 2026/11/5
-
Rating change
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)TipRanks · 2026/9/21
-
Company notice
Recursion Pharmaceuticals | SCHEDULE 13G/A: OthersSEC · 2026/11/14
-
Recursion Pharmaceuticals Q3 EPS $(0.22), Inline, Sales $18.552M Beat $14.783M EstimateBenzinga · 2026/11/3
-
Company notice
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan FredSEC · 2026/11/5
-
Rating change
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price TargetBenzinga · 2026/10/19
-
Rating change
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)TipRanks · 2026/10/19
-
Rating change
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Announces Target Price $6Market Newswire · 2026/10/16
-
Company notice
Recursion Pharmaceuticals | SCHEDULE 13G: OthersSEC · 2026/11/10
-
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6Market Newswire · 2026/11/4
-
Company notice
Recursion Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Hassan FredSEC · 2026/11/5
-
Rating change
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3Market Newswire · 2026/8/17
-
Company notice
Recursion Pharmaceuticals | 424B5: ProspectusSEC · 2026/10/16
-
Company notice
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HERSHBERG ROBERTSEC · 2026/10/8
-
Company notice
Recursion Pharmaceuticals | 8-K: Current reportSEC · 2026/10/15
-
Rating change
J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy RatingMarket Newswire · 2026/9/16
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:59:48 · For reference only, not investment advice and not tailored to your situation.
Recursion Pharmaceuticals discussion 0 comments